The amount of additional milestone payments payable to the acquiree shareholders.

No definition available.

Name:	hepa_MergerAgreementAdditionalMilestonePaymentsPayableToAcquireeShareholder
Namespace Prefix:	hepa_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585

+ Details

Name:	us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	hepa_MergerAgreementsAxis=hepa_MergerAgreementUponReceiptOfPhaseIiPositiveDataMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	hepa_MergerAgreementsAxis=hepa_MergerAgreementUponInitiationOfPhaseIiiTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	hepa_MergerAgreementsAxis=hepa_MergerAgreementUponAcceptanceByFDOfNewDrugMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=hepa_CiclofilinPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	hepa_MergerAgreementsAxis=hepa_MergerAgreementUponPositiveAnalysisOfPhaseIIbTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	hepa_MergerAgreementsAxis=hepa_MergerAgreementUponApprovalByFDAOfNewDrugMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Subsequent Events (Details) - USD ($)		1 Months Ended	3 Months Ended
Subsequent Events (Details) - USD ($)	Jan. 14, 2022	Oct. 31, 2018	Dec. 31, 2018
Merger Agreement, Upon Receipt of Phase II Positive Data
Subsequent Events
Additional milestone payments payable		$ 3,000,000
Merger Agreement, Upon Initiation of Phase III Trial
Subsequent Events
Additional milestone payments payable		5,000,000
Merger Agreement, Upon Acceptance By FDA of New Drug
Subsequent Events
Additional milestone payments payable		$ 8,000,000
Ciclofilin
Subsequent Events
Percentage of issued and outstanding		2.50%	2.50%
Payment of contingent consideration milestone		$ 700,000	$ 1,000,000
Subsequent Event \| Merger Agreement, Upon Receipt of Phase II Positive Data
Subsequent Events
Additional milestone payments payable	$ 3,000,000
Subsequent Event \| Merger Agreement, Upon Initiation of Phase III Trial
Subsequent Events
Additional milestone payments payable	$ 5,000,000
Subsequent Event \| Ciclofilin
Subsequent Events
Percentage of issued and outstanding	7.50%
Payment of contingent consideration milestone	$ 2,000,000
Subsequent Event \| Ciclofilin \| Merger Agreement, Upon Positive Analysis of Phase IIb Trial
Subsequent Events
Additional milestone payments payable	1,000,000
Subsequent Event \| Ciclofilin \| Merger Agreement, Upon Acceptance By FDA of New Drug
Subsequent Events
Additional milestone payments payable	5,000,000
Subsequent Event \| Ciclofilin \| Merger Agreement Upon Approval by FDA Of New Drug
Subsequent Events
Additional milestone payments payable	$ 8,000,000